Twelve recognised for outstanding results in Medicine Australia’s Continuing Education Program
26 April 2023: Medicines Australia congratulates twelve individuals, from the pharmaceutical and health sector, for receiving Medicines Australia’s Continuing Education Program (CEP) Awards, which recognise their outstanding results and in depth understanding of the industry gathered during the 2022 course.
Now in their 26th year, the prestigious CEP Awards includes three categories that recognise academic excellence and results achieved during the online course. The CEP educates pharmaceutical company representatives, and those working in industry, to a very high ethical standard so they can provide healthcare professionals with accurate, balanced information to support the quality use of medicines.
The 2022 awards recipients are:-
- University of Tasmania (UTAS) Excellence Award: Matthew Nicolaides (Seqirus), and Ahmed Fouad (Galderma) for being high achieving, committed, dedicated and personally engaged throughout Semesters 1 and 2 respectively.
- The Code of Conduct Award: Matthew Nicolaides (Seqirus)whoachieved the highest mark for Program 1 (The Medicines Australia Code of Conduct)
- The CEP Achievement Award: The following 10 students received this Award for achieving the 10 highest aggregate marks for the majority of the core programs:
|Nicholas Smith||Boehringer Ingelheim|
|Theresa Wade||WriteSource Medical|
|Nicky Schmidt||Novartis Pharmaceuticals|
|Nadia Lokananta||Eli Lilly|
|Dinesh Sukhavasi||Boehringer Ingelheim|
“We have been extremely impressed with the level of participation and outstanding results achieved in the 2022 CEP course,” said Elizabeth de Somer, Medicines Australia CEO. “This is an intensive, in-depth course delivered by our partners, the University of Tasmania, and we wish to extend our congratulations to all the award recipients – and also those who successfully completed the program last year.
“It’s wonderful to see the industry’s continued dedication to educating and assisting medical representatives, who serve as crucial liaisons between healthcare professionals and pharmaceutical companies. The collective expertise from this program will prove valuable to both companies and the wider healthcare system,” added Ms de Somer.
Joanne Catubay, a CEP Achievement Award winner from DKSH said, “Medicine Australia’s CEP has helped me evolve from being just a target-oriented medical sales representative, to becoming a more conscientious, ethical and patient-oriented part of the bigger Australian health system. I am grateful not only for the recognition but more importantly for the valuable learning.”
Benjamin McVean, another CEP Achievement Award winner from Pfizer added “The Medicines Australia CEP helped me understand the complex industry and what is expected to be able to provide the right support to healthcare practitioners and thereby their patients.”
The CEP Program is offered online through the University of Tasmania, with 2023 Semester One enrolments closing this week on 28 April 2023. Awards for the 2023 CEP Program will be announced in early 2024.
For further information, please contact:
Anne-Marie Sparrow on 0417 421 email@example.com
ABOUT THE CONTINUING EDUCATION PROGRAM (CEP)
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard.
The CEP is primarily directed at medical representatives working within the prescription medicines industry but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
The CEP contains six core programs, designed to guide medical representatives through the information, knowledge and skills required in the performance of their professional duties. More information is available on the Medicines Australia website.